Physician profile
Hersh Patel
NPI 1992969703
$3,715.23
in general payments reported to CMS, 2019-2025
30 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $67.92 · 2022: $117 · 2023: $746 · 2024: $1,333 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $788.87 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $426.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $312.51 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $303.15 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.51 | 2023-2025 | Xifaxan |
| Amgen INC. | $230.19 | 2020-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.28 | 2019-2025 | Jardiance |
| Pfizer INC. | $189.21 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.28 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $166.62 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astrazeneca Pharmaceuticals LP | $119.48 | 2019-2024 | Airsupra, Breztri |
| Astellas Pharma US INC | $53.93 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $48.62 | 2019-2020 | |
| Dexcom, INC. | $47.24 | 2024-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $45.33 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $41.76 | 2022 | |
| Sanofi-Aventis U.S. LLC | $31.38 | 2019 | |
| Edwards Lifesciences Corporation | $30.07 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals International, Plc | $28.91 | 2024 | Arcalyst |
| Vertex Pharmaceuticals Incorporated | $26.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.78 | 2024 | |
| Agios Pharmaceuticals, INC. | $24.54 | 2025 | Pyrukynd |
| Mayne Pharma Commercial LLC | $23.62 | 2025 | |
| Sumitomo Pharma America, INC. | $22.43 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $22.24 | 2024 | Heplisav-B |
| Globus Medical, INC. | $21.17 | 2025 | Senza |
| Abbvie INC. | $16.51 | 2025 | |
| Currax Pharmaceuticals LLC | $15.51 | 2023 | Contrave, Nexlizet, Nexletol |
| Mylan Specialty L.P. | $14.95 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hersh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.